914P The landscape of somatic copy number alterations of head and neck squamous cell carcinoma across different anatomic sitesSep 17, 2024 | Alberto Carral Maseda, Comunicaciones a congresos, ESMO
871P Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC studySep 2, 2024 | Comunicaciones a congresos, ESMO
517P Real-world efficacy and safety of immune checkpoint inhibitors (ICI) in gastrointestinal tumors with mismatch repair deficiency or microsatellite instability (dMMR/MSI-H)Jun 26, 2024 | Comunicaciones a congresos, ESMO, Marta Covela Rúa
Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim of the atezobladderpreserve phase II trial (SOGUG-2017-A-IEC(VEJ)-4).May 29, 2024 | ASCO, Comunicaciones a congresos, Pilar Canoa Román, Sergio Vazquez-Estevez
Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.Ene 22, 2024 | Alberto Carral Maseda, ASCO, Borja Gonzalez Gómez, Comunicaciones a congresos
P-277 Real-world efficacy, safety, and impact of the GIPI score of nivolumab in advanced esophageal squamous cell carcinoma (ESCC) refractory or intolerant to prior chemotherapy in European population: The EPIC trialJul 1, 2023 | Alberto Carral Maseda, Comunicaciones a congresos, ESMO
